title: Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
abstract: OBJECTIVE
  To assess vitreous vascular endothelial growth factor (VEGF) concentrations in proliferative diabetic retinopathy (PDR) in comparison to proliferative vitreoretinopathy (PVR).
  
  
  METHODS
  Vitreous samples were collected from 69 eyes of 69 patients with traumatic lens dislocation (n = 10), grade B PVR with rhegmatogenous retinal detachment (n = 13), grade C PVR with rhegmatogenous retinal detachment (n = 14), PDR with vitreous hemorrhage (n = 18), and PDR with vitreous hemorrhage and tractional retinal detachment (n = 14). Vitreous fluid samples were obtained at vitrectomy, and the levels of VEGF were measured by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  The mean vitreous level of VEGF was 15.14 ± 5.22 pg/ml in eyes with grade B PVR, 99.15 ± 38.58 pg/ml in eyes with grade C PVR, 4,534.01 ± 1,193.28 pg/ml in eyes with vitreous hemorrhage secondary to PDR, 5,157.29 ± 969.44 pg/ml in eyes with vitreous hemorrhage and tractional retinal detachment secondary to PDR, and 16.19 ± 5.76 pg/ml in eyes of the control group with traumatic lens dislocation. Vitreous VEGF concentrations were significantly higher in the patients with grade C PVR, PDR with vitreous hemorrhage and PDR with vitreous hemorrhage and tractional retinal detachment in comparison to the control patients (p < 0.05). A significant alteration was not observed in patients with grade B PVR (p = 0.55).
  
  
  CONCLUSIONS
  Vitreous VEGF concentrations are increased in PDR and grade C PVR. The high VEGF concentrations could suggest a possible effect of VEGF on advanced PVR.
authors.affiliation: SB Ankara Ulucanlar Eye Education and Research Hospital, SB Ankara Kecioren Education and Research Hospital, Ankara, Turkey. mcitirik@hotmail.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Citirik
authors.forename: Emrah Utku
authors.initials: EU
authors.lastname: Kabatas
authors.forename: Cosar
authors.initials: C
authors.lastname: Batman
authors.forename: Kadir Okhan
authors.initials: KO
authors.lastname: Akin
authors.forename: Naciye
authors.initials: N
authors.lastname: Kabatas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003930:Diabetic Retinopathy / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012163:Retinal Detachment / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D014821:Vitrectomy; D018630:Vitreoretinopathy, Proliferative / Q000378:metabolism*; D014822:Vitreous Body / Q000378:metabolism*; D014823:Vitreous Hemorrhage / Q000378:metabolism; D055815:Young Adult
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A